Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 16 2025
0mins
Should l Buy BMY?
Source: Benzinga
Greenlight Capital's Q2 2025 Trades: The hedge fund, led by David Einhorn, has initiated new positions in Fluor Corp. and Victoria’s Secret & Co., while exiting its stake in Varex Imaging Corp. It also adjusted existing holdings, increasing stakes in Albireo Pharma and Amgen, and reducing investments in Activision Blizzard and Bristol Myers Squibb.
Investment Strategy Insights: These trades reflect Greenlight Capital's dynamic investment strategy, indicating confidence in the future performance of Fluor and Victoria’s Secret, while suggesting a cautious outlook on Varex Imaging and other reduced holdings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 62.340
Low
37.00
Averages
55.86
High
68.00
Current: 62.340
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb: A High Dividend Investment Opportunity
- Dividend Yield Advantage: Bristol Myers Squibb currently offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors.
- Market Competition and Opportunities: Despite operating in a highly competitive pharmaceutical market, Bristol Myers Squibb focuses on cardiovascular, cancer, and immune-related drugs, which present substantial market potential, especially as GLP-1 weight-loss drugs gain attention.
- Price Recovery Potential: With a current stock price of $62.37, approximately 25% below its late 2022 highs, there is recovery potential for investors, and the company's 70% payout ratio indicates a solid commitment to maintaining dividends.
- Patent Protection and Growth Foundation: While Bristol Myers Squibb's Opdivo cancer drug will lose patent protection in 2028, the company is developing alternative delivery methods to extend its patent life, and its pipeline includes other drugs, showcasing its ongoing growth potential.
See More
ImmunityBio Earnings Preview and Market Reaction
- Earnings Expectations: ImmunityBio is projected to report FY2025 revenue of $113.3 million, a staggering 700% increase from $14.8 million in 2024, while losses per share are expected to improve to $0.38, indicating significant progress in its commercialization efforts.
- Anktiva's Strong Performance: Anktiva generated $113 million in net product revenue for 2025, marking a 700% year-over-year increase, with Q4 revenue soaring 431% to $38.3 million, surpassing market expectations and reflecting robust demand in the market.
- Promotion of IL-15 Mechanism: Founder Soon-Shiong has highlighted Anktiva's IL-15 mechanism in media appearances, emphasizing its potential in cancer treatment, particularly in combination with Merck's Keytruda, which may enhance efficacy and improve cancer-free rates for patients.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for IBRX has turned 'bullish' amid a 185% surge in message volume over 24 hours, with investors expressing optimistic price predictions that could drive the stock price rapidly upward, with some users forecasting it could reach $20.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
FourWorld Capital Increases Stake in Sable Offshore Corp.
- Increased Holdings: FourWorld Capital Management LLC acquired 8,105,608 shares of Sable Offshore Corp. in Q4 2025, valued at $73.11 million, making it the fund's largest holding at 62.89% of AUM.
- Stock Performance: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, significantly underperforming the S&P 500 by 86.44 percentage points, indicating severe competitiveness issues in the market.
- Legal Challenges: Sable Offshore faces major legal hurdles; despite federal approval for the restart of its Las Flores pipeline in California, environmental groups filed lawsuits to halt it, and a recent court ruling against the company could increase stock volatility.
- Investment Risks: While the significant drop in Sable Offshore's stock price makes it a relatively cheap investment, its future success will heavily depend on resolving ongoing legal issues, categorizing it as a high-risk buy at this time.
See More
FourWorld Capital Management Acquires Major Stake in Sable Offshore Corp.
- New Investment Position: According to a February 17, 2026 SEC filing, FourWorld Capital Management acquired 8,105,608 shares of Sable Offshore Corp. valued at $73.11 million, making it the fund's largest holding at 62.9% of reportable AUM.
- Portfolio Structure Shift: As of December 31, 2025, Sable Offshore's holding value of $73.11 million significantly overshadows other holdings, with IWM and BMY making up less than 5%, indicating FourWorld's strong conviction in this investment.
- Stock Volatility Risk: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, facing legal challenges that could increase future stock volatility, necessitating cautious risk assessment by investors.
- Legal Challenges Impact: Although Sable Offshore received federal approval to restart its Las Flores pipeline in California, lawsuits from environmental groups and a judge's ruling against the restart hinder progress, with ongoing legal battles likely to directly affect the company's operations and stock performance.
See More
Bristol Myers Squibb: A High Dividend Investment Opportunity
- Dividend Yield Advantage: Bristol Myers Squibb currently offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors.
- Market Competition and Opportunities: Despite operating in a highly competitive pharmaceutical market, Bristol Myers Squibb focuses on cardiovascular, cancer, and immune-related drugs, which present substantial market potential, especially as GLP-1 weight-loss drugs gain attention.
- Price Recovery Potential: With a current stock price of $62.37, approximately 25% below its late 2022 highs, there is recovery potential for investors, and the company's 70% payout ratio indicates a solid commitment to maintaining dividends.
- Patent Protection and Growth Foundation: While Bristol Myers Squibb's Opdivo cancer drug will lose patent protection in 2028, the company is developing alternative delivery methods to extend its patent life, and its pipeline includes other drugs, showcasing its ongoing growth potential.
See More
ImmunityBio Earnings Preview and Market Reaction
- Earnings Expectations: ImmunityBio is projected to report FY2025 revenue of $113.3 million, a staggering 700% increase from $14.8 million in 2024, while losses per share are expected to improve to $0.38, indicating significant progress in its commercialization efforts.
- Anktiva's Strong Performance: Anktiva generated $113 million in net product revenue for 2025, marking a 700% year-over-year increase, with Q4 revenue soaring 431% to $38.3 million, surpassing market expectations and reflecting robust demand in the market.
- Promotion of IL-15 Mechanism: Founder Soon-Shiong has highlighted Anktiva's IL-15 mechanism in media appearances, emphasizing its potential in cancer treatment, particularly in combination with Merck's Keytruda, which may enhance efficacy and improve cancer-free rates for patients.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for IBRX has turned 'bullish' amid a 185% surge in message volume over 24 hours, with investors expressing optimistic price predictions that could drive the stock price rapidly upward, with some users forecasting it could reach $20.
See More
Five Key Principles of Innovation
- Importance of Innovation Culture: Lorraine Marchand emphasizes that successful organizations foster a culture that reframes failure as a learning opportunity, encouraging experimentation and allowing employees to freely express new ideas, thereby enhancing the organization's innovative capacity.
- Investment Strategy in Risk: She notes that successful companies often follow a 70/20/10 investment ratio, with 10% allocated to uncertain innovation projects, a strategy validated by Google's success, indicating that appropriate risk investment can significantly drive company growth.
- Customer-First Strategy: Marchand points out that many companies fail to adjust to changing customer demands, leading to market failures; therefore, investors should focus on a company's customer-oriented strategies to avoid failures similar to those of Blockbuster and Kodak.
- Collaboration and Change Management: She highlights that collaboration has become a strategic imperative for corporate success, and organizations need to prioritize team collaboration during change to achieve breakthrough growth, ensuring that departments work together towards common objectives.
See More
Acute Ischemic Stroke Market Set for Growth Driven by Innovative Therapies
- Growth Drivers: The acute ischemic stroke market is expected to experience significant growth from 2026 to 2036, primarily driven by increased awareness of symptoms, advancements in acute stroke care, and a robust pipeline of new therapies, particularly lenzocimab, DM199, and milvexian.
- Market Size Forecast: By 2036, the acute ischemic stroke treatment market is projected to continue expanding, with the United States holding the largest market share; in 2025, approximately 1.8 million new cases of acute ischemic stroke are expected in the 7MM, indicating strong market demand.
- Clinical Progress of New Therapies: Several innovative acute ischemic stroke drugs are currently in clinical trials, including Acticor Biotech's Glenzocimab and DiaMedica Therapeutics' DM199, which are anticipated to transform the market landscape by providing more effective treatment options in the coming years.
- Challenges and Opportunities: While the acute ischemic stroke market faces challenges from high mortality and morbidity rates, the launch of new drugs and advancements in stem cell therapies present significant opportunities for pharmaceutical companies, likely driving long-term growth in the industry.
See More
FourWorld Capital Increases Stake in Sable Offshore Corp.
- Increased Holdings: FourWorld Capital Management LLC acquired 8,105,608 shares of Sable Offshore Corp. in Q4 2025, valued at $73.11 million, making it the fund's largest holding at 62.89% of AUM.
- Stock Performance: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, significantly underperforming the S&P 500 by 86.44 percentage points, indicating severe competitiveness issues in the market.
- Legal Challenges: Sable Offshore faces major legal hurdles; despite federal approval for the restart of its Las Flores pipeline in California, environmental groups filed lawsuits to halt it, and a recent court ruling against the company could increase stock volatility.
- Investment Risks: While the significant drop in Sable Offshore's stock price makes it a relatively cheap investment, its future success will heavily depend on resolving ongoing legal issues, categorizing it as a high-risk buy at this time.
See More
FourWorld Capital Management Acquires Major Stake in Sable Offshore Corp.
- New Investment Position: According to a February 17, 2026 SEC filing, FourWorld Capital Management acquired 8,105,608 shares of Sable Offshore Corp. valued at $73.11 million, making it the fund's largest holding at 62.9% of reportable AUM.
- Portfolio Structure Shift: As of December 31, 2025, Sable Offshore's holding value of $73.11 million significantly overshadows other holdings, with IWM and BMY making up less than 5%, indicating FourWorld's strong conviction in this investment.
- Stock Volatility Risk: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, facing legal challenges that could increase future stock volatility, necessitating cautious risk assessment by investors.
- Legal Challenges Impact: Although Sable Offshore received federal approval to restart its Las Flores pipeline in California, lawsuits from environmental groups and a judge's ruling against the restart hinder progress, with ongoing legal battles likely to directly affect the company's operations and stock performance.
See More
